New Independent Trial Data Supports Potential of Veyonda
Filed with ASX · · 4 pages · English
• New independent clinical trial supportsCompany’s aimfor Veyonda to become a standard companion drug for major anti-cancer therapies • WARMTH study is first reported large-scale multi-national study of Novartis 177 experimental drug, lutetium-PSMA-617, in late-stage prostate cancer and showed a median overall survival (mOS) of 11.6 months 177 • This compares to the LuPIN trial (Veyonda + lutetium
Story so far
Earlier from Noxopharm
- Veyonda to Begin First-Line Sarcoma Treatment Testing
- Veyonda FDA Approved Trial to Commence
- Publications Positive Review of Veyonda in Chemotherapy
- Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm
- March Quarterly Activities Report and Appendix 4C
Later from Noxopharm
- Noxopharm Set to Benefit From Novartis ASCO Data
- DARRT-2 Study Update and Clarification
- Noxopharm Secures Key European Patent Allowance for Veyonda
- DARRT-2 Study Receives IND Approval from FDA
- June 2021 Quarterly Activities Report and Appendix 4C
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm